QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Article 20 Pharmacovigilance Procedures for Centrally Authorised Medicines

Test your understanding of the concepts covered by Article 20 Pharmacovigilance Procedures for Centrally Authorised Medicines.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the central question in the benefit-risk assessment during an Article 20 procedure?

Whether the medicine has any risk at all Whether every reported event is causally related to treatment Whether the benefit-risk balance remains favourable under the authorised or proposed conditions of use Whether the company can avoid changing the product information

Question 2 of 10 Which record would best support inspection readiness for an Article 20 procedure?

Only the final product-information text Only the public EMA announcement A traceable chain linking the safety evidence, internal assessments, submissions, regulatory outcome, implementation and continuing monitoring A summary of the commercial impact of the decision

Question 3 of 10 A serious safety concern arises for a centrally authorised medicine and immediate protective action is considered essential. Which statement best reflects the article's description of possible national action?

A Member State can never act because the product has a Union authorisation A Member State may suspend use in its territory under the applicable urgent protective mechanism pending a definitive decision A Member State must permanently revoke the Union marketing authorisation The MAH may suspend the product throughout the EU without regulatory involvement

Question 4 of 10 Which set of documents should be distinguished because each has a different function in the regulatory chain?

Signal report, case narrative and sales report PRAC recommendation, CHMP opinion and Commission decision SmPC, package leaflet and labelling only RMP, database query and audit report

Question 5 of 10 Which combination best defines the scope of an Article 20 pharmacovigilance procedure?

Any suspected adverse reaction involving a medicinal product marketed in the EU Pharmacovigilance data indicating that regulatory action may be required for centrally authorised medicinal products Any quality defect affecting a centrally authorised medicinal product Any safety concern formally submitted by a marketing authorisation holder

Question 6 of 10 Which body performs the principal pharmacovigilance assessment in an Article 20 procedure?

The European Commission CHMP PRAC The affected Member State alone

Question 7 of 10 How should an MAH express scientific disagreement with an emerging PRAC interpretation?

State that the committee is incorrect without discussing evidence Identify the precise point of disagreement, present supporting evidence, acknowledge contrary evidence and explain the regulatory consequence Withhold all disagreement until after the Commission decision Replace the scientific discussion with commercial arguments

Question 8 of 10 What is the MAH's position regarding formal initiation of an Article 20 pharmacovigilance procedure?

The MAH may directly trigger the procedure by submitting a request to PRAC The MAH may trigger the procedure if it believes urgent action is needed The MAH cannot formally initiate the procedure but can provide information and participate in the assessment The MAH initiates the procedure jointly with the European Commission

Question 9 of 10 Which statement best describes the QPPV's responsibility after an Article 20 outcome?

The QPPV must personally perform every implementation task The QPPV's involvement ends when the Commission decision is published The QPPV should oversee whether the pharmacovigilance consequences are appropriately incorporated into the company's system The QPPV is responsible for adopting the Commission decision

Question 10 of 10 Why should implementation of an Article 20 decision be treated as more than a product-information update?

Product information is unrelated to pharmacovigilance The regulatory conclusion may alter signal management, RMP activities, risk-minimisation evaluation and ongoing monitoring Only national authorities can implement product-information changes Article 20 decisions automatically require a new marketing authorisation application

Knowledge Assessment: Article 20 Pharmacovigilance Procedures for Centrally Authorised Medicines

Cookie Settings